在临床前阿尔茨海默氏症发展期间的肥胖症加剧了大脑代谢衰退
Thea Anderson1, Sumeet Sharma2, Michael A Kelberman3
1Neuroscience Institute, Georgia State University, Atlanta, Georgia, USA.
Journal of neurochemistry
|June 30, 2023
概括
中年肥胖加快了阿尔茨海默病 (AD) 的进展,因为它损害了记忆力和大脑代谢. 高脂肪饮食在临床前AD大鼠中加剧了认知衰退和大脑变化,突出显示了饮食在疾病发展中的作用.
科学领域:
- 神经科学是一个神经科学.
- 代谢性疾病是一种代谢性疾病.
- 基因组学就是基因组学.
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,中年肥胖被确定为一个重要的危险因素.
- 中年时期的肥胖,而不是晚年,与AD风险和严重程度的增加有关,这表明在临床前AD期间有一个关键窗口.
- 阿尔茨海默病理在症状出现前几十年就开始,涉及粉样β积累,陶过,代谢功能障碍和神经炎症.
研究的目的:
- 调查在临床前AD期间以西方饮食诱导肥胖是否会加剧背部海马体 (dHC) 中的大脑代谢功能障碍.
- 分析在公元早期西方饮食中的老鼠dHC的转录组变化.
- 评估饮食对AD认知功能和神经化学的长期影响.
主要方法:
- 在年轻的成年TgF344-AD大鼠和野生类型 (WT) 控制群中对背部海马体 (dHC) 的转录组分析,这些对象被食西方饮食或标准食.
- 评估dHC-依赖的空间工作记忆.
- 在长期饮食干预后,测量老老鼠的dHC单胺水平.
主要成果:
- 西方饮食诱导了对线粒体和神经传递通路的调节失调,并在AD大鼠的dHC中增加了胆固醇合成基因.
- 饮食扩大了AD和WT大鼠之间的基因表达差异,影响了诺亚上腺体信号传递和脂质运输.
- 西方饮食损害了AD大鼠的空间工作记忆,改变了北上腺素 (NE) 水平,减少了NE的丰度,减轻了NE的周转量增加.
结论:
- 在预发性AD期间的肥胖会损害记忆力,并增强AD诱导的代谢下降,可能涉及胆固醇的过度生产.
- 在临床前AD期间的饮食干预可以加速认知衰退并改变大脑神经化学.
- 这些发现强调了中年代谢健康在阿尔茨海默病的发病和进展中的关键作用.
相关概念视频
Alzheimer's Disease: Overview
527
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
527
Obesity
544
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
544
Alzheimer's Disease: Treatment
220
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220


